Cargando…

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma

AIMS: To evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS). METHODS: Forty-six symptomatic MM patients were included in this study who had a prior high level o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Yujun, Wang, Jinying, Chen, Fei, Li, Xin, Zhang, Jiajia, Shen, Man, Tang, Ran, Huang, Zhongxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919723/ https://www.ncbi.nlm.nih.gov/pubmed/35296015 http://dx.doi.org/10.3389/fonc.2022.808290

Ejemplares similares

Analysis of the Metabolic Characteristics of Serum Samples in Patients With Multiple Myeloma
por: Du, Haiwei, et al.
Publicado: (2018)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Ixazomib‐based maintenance therapy after bortezomib‐based induction in patients with multiple myeloma not undergoing transplantation: A real‐world study
por: Shen, Man, et al.
Publicado: (2021)

Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report
por: An, Na, et al.
Publicado: (2015)

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma
por: Gao, Dandan, et al.
Publicado: (2023)

Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridization
por: Hu, Ying, et al.
Publicado: (2016)

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics
por: Alonso, Rafael, et al.
Publicado: (2022)

Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
por: Mejia Saldarriaga, Mateo, et al.
Publicado: (2022)

Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma
por: Liu, Rui, et al.
Publicado: (2021)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma
por: Fei, Fei, et al.
Publicado: (2022)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
por: Keller, Alana L., et al.
Publicado: (2022)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

An emerging prognosis prediction model for multiple myeloma: Hypoxia-immune related microenvironmental gene signature
por: Yu, Zhengyu, et al.
Publicado: (2022)

Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients
por: Yan, Ge, et al.
Publicado: (2022)

HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma
por: Yang, Ying, et al.
Publicado: (2021)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
por: Cheng, Qianwen, et al.
Publicado: (2021)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples
por: Chanukuppa, Venkatesh, et al.
Publicado: (2021)

Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
por: Cárdenas, Maria Cruz, et al.
Publicado: (2022)

Dual Targeting of Multiple Myeloma Stem Cells and Myeloid-Derived Suppressor Cells for Treatment of Chemotherapy-Resistant Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

Clinical features and prognosis of multiple myeloma and orbital extramedullary disease: Seven cases report and review of literature
por: Hu, Wan-Li, et al.
Publicado: (2022)

Current Role of Radiation Therapy for Multiple Myeloma
por: Talamo, Giampaolo, et al.
Publicado: (2015)

An Uncommon Cause of Acute Encephalopathy in Multiple Myeloma
por: Al Zeyoudi, Jawaher, et al.
Publicado: (2021)

PET/CT in Multiple Myeloma: Beyond FDG
por: Matteucci, Federica, et al.
Publicado: (2021)

Editorial: T-cell directed therapies in multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2023)

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2019)

PIWIL1 Drives Chemoresistance in Multiple Myeloma by Modulating Mitophagy and the Myeloma Stem Cell Population
por: Wang, Yajun, et al.
Publicado: (2022)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
por: Wang, Ting, et al.
Publicado: (2022)

Integrated Transcriptomic Analysis Reveals a Distinctive Role of YAP1 in Extramedullary Invasion and Therapeutic Sensitivity of Multiple Myeloma
por: Zheng, Bo, et al.
Publicado: (2022)

Development and Validation of a 9-Gene Prognostic Signature in Patients With Multiple Myeloma
por: Liu, Xiao-Ping, et al.
Publicado: (2019)

Multiple myeloma and physical activity: a scoping review
por: Smith, Lee, et al.
Publicado: (2015)

Multiple myeloma with testicular involvement: A case report
por: Yamashita, Kaori, et al.
Publicado: (2019)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4610lfb1ghk4k1g7ponidm38oj